NO20073370L - Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav - Google Patents

Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav

Info

Publication number
NO20073370L
NO20073370L NO20073370A NO20073370A NO20073370L NO 20073370 L NO20073370 L NO 20073370L NO 20073370 A NO20073370 A NO 20073370A NO 20073370 A NO20073370 A NO 20073370A NO 20073370 L NO20073370 L NO 20073370L
Authority
NO
Norway
Prior art keywords
tyrosine kinase
protein tyrosine
kinase inhibitors
pharmaceutical applications
combinations including
Prior art date
Application number
NO20073370A
Other languages
English (en)
Norwegian (no)
Inventor
Paul M J Mcsheehy
Jerry Min-Jian Huang
Anandhi Ranganathan Johri
Ronald Richard Linnartz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118322&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073370(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20073370L publication Critical patent/NO20073370L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20073370A 2004-11-30 2007-06-29 Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav NO20073370L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63183704P 2004-11-30 2004-11-30
PCT/US2005/042975 WO2006060331A1 (fr) 2004-11-30 2005-11-28 Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques

Publications (1)

Publication Number Publication Date
NO20073370L true NO20073370L (no) 2007-06-29

Family

ID=36118322

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073370A NO20073370L (no) 2004-11-30 2007-06-29 Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav

Country Status (29)

Country Link
US (2) US20080139587A1 (fr)
EP (1) EP1819331B1 (fr)
JP (1) JP2008521826A (fr)
KR (1) KR20070088653A (fr)
CN (1) CN101065127A (fr)
AT (1) ATE445398T1 (fr)
AU (1) AU2005312061B2 (fr)
BR (1) BRPI0518733A2 (fr)
CA (1) CA2584163A1 (fr)
CY (1) CY1110559T1 (fr)
DE (1) DE602005017181D1 (fr)
DK (1) DK1819331T3 (fr)
ES (1) ES2333348T3 (fr)
HK (1) HK1109059A1 (fr)
HR (1) HRP20100012T1 (fr)
IL (1) IL183138A (fr)
JO (1) JO2596B1 (fr)
MA (1) MA29032B1 (fr)
MX (1) MX2007006371A (fr)
NO (1) NO20073370L (fr)
NZ (1) NZ554552A (fr)
PL (1) PL1819331T3 (fr)
PT (1) PT1819331E (fr)
RU (1) RU2423980C2 (fr)
SI (1) SI1819331T1 (fr)
TN (1) TNSN07212A1 (fr)
TW (1) TW200630091A (fr)
WO (1) WO2006060331A1 (fr)
ZA (1) ZA200703196B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CA2799202C (fr) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions et procedes de traitement de maladies auto-immunes et autres
CN102134246A (zh) * 2011-01-06 2011-07-27 王文怡 一种埃博霉素衍生物及其制备和药物应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2879675B1 (fr) 2012-08-06 2019-11-13 Duke University Composés et procédés pour le ciblage de hsp90
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2017184956A1 (fr) 2016-04-22 2017-10-26 Duke University Composés et procédés de ciblage de hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3826988A4 (fr) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC Composés, dérivés et analogues contre le cancer
WO2021185844A1 (fr) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Utilisation d'une substance et composition pharmaceutique correspondante et traitements médicaux ou utilisations correspondants
WO2021233534A1 (fr) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Utilisation d'une substance et composition pharmaceutique associée, et traitements médicaux ou utilisations associées
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022047259A1 (fr) 2020-08-28 2022-03-03 California Institute Of Technology Circuits de signalisation de mammifère synthétiques pour la régulation de population cellulaire robuste
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
WO2024030441A1 (fr) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Procédés d'amélioration d'une thérapie cellulaire avec des complexes d'organites

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE60130017T2 (de) * 2000-11-22 2008-05-15 Novartis Ag Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
CN1511036B (zh) * 2001-02-27 2010-05-05 诺瓦提斯公司 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
WO2003103712A1 (fr) * 2002-06-01 2003-12-18 Novartis Ag Combinaisons comprenant des epothilones, et utilisations pharmaceutiques de celles-ci
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
JO2596B1 (en) 2011-02-27
WO2006060331A1 (fr) 2006-06-08
CA2584163A1 (fr) 2006-06-08
EP1819331A1 (fr) 2007-08-22
TW200630091A (en) 2006-09-01
ZA200703196B (en) 2009-08-26
DE602005017181D1 (de) 2009-11-26
IL183138A0 (en) 2008-04-13
AU2005312061B2 (en) 2009-09-03
AU2005312061A1 (en) 2006-06-08
ES2333348T3 (es) 2010-02-19
EP1819331B1 (fr) 2009-10-14
PT1819331E (pt) 2009-11-30
SI1819331T1 (sl) 2010-02-26
MA29032B1 (fr) 2007-11-01
JP2008521826A (ja) 2008-06-26
HK1109059A1 (en) 2008-05-30
NZ554552A (en) 2011-05-27
KR20070088653A (ko) 2007-08-29
RU2423980C2 (ru) 2011-07-20
MX2007006371A (es) 2007-06-20
TNSN07212A1 (en) 2008-11-21
PL1819331T3 (pl) 2010-03-31
BRPI0518733A2 (pt) 2008-12-02
ATE445398T1 (de) 2009-10-15
HRP20100012T1 (hr) 2010-02-28
IL183138A (en) 2011-03-31
US20110190312A1 (en) 2011-08-04
US20080139587A1 (en) 2008-06-12
RU2007124492A (ru) 2009-04-10
CN101065127A (zh) 2007-10-31
CY1110559T1 (el) 2015-04-29
DK1819331T3 (da) 2010-01-04

Similar Documents

Publication Publication Date Title
NO20073370L (no) Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CR20120244A (es) Inhibidores de la tirosina quinasa de bruton
CY2013014I1 (el) Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
DK1784396T3 (da) Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
NO20090628L (no) Pyridizinon derivativater
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
EA200801430A1 (ru) Производные триазола
WO2005108416A3 (fr) Inhibiteurs de kinase a chaine legere de myosine et procede d'utilisation
DK2094699T3 (da) Hidtil ukendte imidazolonderivater, fremstilling deraf som lægemidler, farmaceutiske præparater og anvendelse deraf som hæmmere af proteinkinaser, især cdc7
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5
DK1912954T3 (da) Hidtil ukendte cysteinproteaseinhibitorer og deres terapeutiske applikationer
CL2007001737A1 (es) Compuestos derivados de cianopiridinas; inhibidores de proteina quinasa;composicion farmaceutica;y uso para el tratamiento o inhibicion de un trastorno mediado por una proteina quinasa,tal como enfermedad autoinmune e inflamatoria.
IS8102A (is) Samsetning ras-farnesýltransferasatálma, sýklódextríns og etanóls
CY1115436T1 (el) Αναστολεις της κινασης p70 s6

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application